GlassScriptPhysician profile
Manohar M Alloju
NPI 1053312447
$8,063.98
in general payments reported to CMS, 2019-2025
24 companies · $91.76 in 2025
The $91.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $1,726 · 2021: $1,716 · 2022: $683 · 2023: $433 · 2024: $2,285 · 2025: $91.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,054 · Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,053.80 |
| Food and Beverage | $756.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $2,053.80 | 2024 | |
| Amarin Pharma, INC. | $1,201.24 | 2019-2023 | |
| Novo Nordisk INC | $1,137.22 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $818.49 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $725.00 | 2020-2021 | |
| Lilly USA, LLC | $565.75 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $275.77 | 2020-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $260.91 | 2021-2025 | Nexletol |
| Pfizer INC. | $150.29 | 2020-2025 | |
| Mylan Specialty L.P. | $147.19 | 2019-2022 | |
| Abbott Laboratories | $121.37 | 2021-2022 | |
| Exact Sciences Corporation | $106.86 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.64 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $85.91 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $64.44 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.59 | 2021 | |
| Merck Sharp & Dohme LLC | $46.15 | 2020 | |
| Gilead Sciences, INC. | $41.51 | 2020-2021 | |
| Genentech USA, INC. | $24.72 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.62 | 2020 | |
| Eisai INC. | $18.94 | 2020 | |
| Astellas Pharma US INC | $18.23 | 2020 | |
| Glaxosmithkline, LLC. | $17.58 | 2020 | |
| Allergan, INC. | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manohar Alloju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.